Alberto Chiappori

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text

Medicine, Oncology, Radiation Oncology +15

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely et al. · The Lancet Oncology · 2014 · 695 citations

Medicine, Oncology, Pharmacology +16

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel et al. · The Lancet Oncology · 2015 · 638 citations · Full text

Medicine, Oncology, Pharmacology +13

Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

Scott Antonia, Noweeda Mirza, Ingo Fricke et al. · Clinical Cancer Research · 2006 · 443 citations · Full text

Medicine, Immunology, Oncology +17